BRAF and metastatic melanoma: According to National Comprehensive Cancer Network (NCCN) guidelines, metastatic melanoma, irrespective of genotype status (BRAF or KIT mutations), can be treated with DTIC, temozolomide and paclitaxel, however, these treatments are not target-specific like BRAF and MEK inhibitors [4].